<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145700</url>
  </required_header>
  <id_info>
    <org_study_id>17306</org_study_id>
    <secondary_id>J1S-MC-JV02</secondary_id>
    <secondary_id>2018-004243-23</secondary_id>
    <nct_id>NCT04145700</nct_id>
  </id_info>
  <brief_title>CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma</brief_title>
  <official_title>A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to test the safety and efficacy of ramucirumab in combination&#xD;
      with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial&#xD;
      sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol&#xD;
      which is a platform to accelerate the development of new treatments for pediatric and young&#xD;
      adult participants with cancer. Your participation in this trial could last 12 months or&#xD;
      longer, depending on how you and your tumor respond.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)]</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR): Percentage of Participants Who Achieve CR</measure>
    <time_frame>Baseline to date of CR (Estimated up to 12 Months)</time_frame>
    <description>CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax)</measure>
    <time_frame>Cycle 1 through Cycle 13 (21 Day Cycles)</time_frame>
    <description>PK: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Minimum Concentration (Cmin)</measure>
    <time_frame>Cycle 1 through Cycle 13 (21 Day Cycles)</time_frame>
    <description>PK: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Baseline through End of Study (Estimated up to 12 Months)</time_frame>
    <description>Number of Participants with Anti-Ramucirumab Antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Synovial Sarcoma</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab, Gemcitabine and Docetaxel given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine and Docetaxel given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Ramucirumab given IV</description>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine given IV</description>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel given IV</description>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have discontinued all previous treatments for cancer or&#xD;
             investigational agents ≥7 days after the last dose or per the type of previous&#xD;
             treatment as stated in the protocol and must have recovered from the acute effects to&#xD;
             ≤Grade 2 for alopecia and decreased tendon reflex and to ≤Grade 1 for all other&#xD;
             effects at the time of enrollment, unless otherwise noted. Consult with the Lilly&#xD;
             clinical research physician or scientist for the appropriate length of time prior to&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          -  Participants with relapsed, recurrent, or refractory SS.&#xD;
&#xD;
          -  Participants must:&#xD;
&#xD;
               -  Have measurable disease by Response Evaluation Criteria in Solid Tumors, Version&#xD;
                  (RECIST) 1.1.&#xD;
&#xD;
               -  have received at least one prior line of systemic treatment (including&#xD;
                  neoadjuvant and adjuvant chemotherapy) that contains ifosfamide and/or&#xD;
                  doxorubicin, or any approved therapies for which they are eligible, unless the&#xD;
                  patient is not a suitable candidate for the approved therapy.&#xD;
&#xD;
               -  not be eligible for surgical resection at time of enrollment.&#xD;
&#xD;
          -  Adequate cardiac function, defined as: Shortening fraction of ≥27% by echocardiogram,&#xD;
             or ejection fraction of ≥50% by gated radionuclide study.&#xD;
&#xD;
          -  Adequate blood pressure (BP) control, defined as:&#xD;
&#xD;
               -  Participants ≥18 years: Controlled hypertension defined as systolic BP ≤150&#xD;
                  millimeters of mercury (mmHg) or diastolic BP ≤90 mmHg where standard medical&#xD;
                  management is permitted. Please note that ≥2 serial BP readings should be&#xD;
                  obtained and averaged to determine baseline BP.&#xD;
&#xD;
               -  Participants &lt;18 years: A BP ≤95th percentile for age, height, and gender&#xD;
                  measured as described in National High Blood Pressure Education Program Working&#xD;
                  Group (NHBPEPWG) on High Blood Pressure in Children and Adolescents (2004), where&#xD;
                  standard medical management is permitted. Please note that ≥2 serial BP readings&#xD;
                  should be obtained and averaged to determine baseline BP.&#xD;
&#xD;
          -  Adequate hematologic function, as defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC): ≥750/microliters (µL) granulocyte-colony&#xD;
                  stimulating factor (G-CSF) permitted up to 48 hours prior. Participants with&#xD;
                  documented history of benign ethnic neutropenia or other conditions could be&#xD;
                  considered with a lower ANC after discussion with and approval from the Lilly&#xD;
                  clinical research physician or scientist.&#xD;
&#xD;
               -  Platelets: ≥75,000/cubic millimeters. Platelet transfusion permitted up to 72&#xD;
                  hours prior.&#xD;
&#xD;
               -  Hemoglobin: ≥8 grams per deciliter (g/dL) (≥80 g/liter). Transfusions to increase&#xD;
                  the participant's hemoglobin level to at least 8 g/dL are permitted; however,&#xD;
                  study treatment must not begin until 7 days after the transfusion, and complete&#xD;
                  blood count criteria for eligibility are confirmed within 24 hr of first study&#xD;
                  dose.&#xD;
&#xD;
          -  Adequate renal function, as defined as:&#xD;
&#xD;
               -  Creatinine clearance or radioscope glomerular filtration rate (GFR) ≥60&#xD;
                  milliliters/minute/meters squared OR serum creatinine meeting the following&#xD;
                  parameters:&#xD;
&#xD;
                    -  for participants ≥18 years of age serum creatinine ≤1.5×upper limit of&#xD;
                       normal (ULN);&#xD;
&#xD;
                    -  for participants &lt;18 years of age, serum creatinine based on age/gender as&#xD;
                       follows: Age 1 to &lt;2 years maximum serum creatinine 0.6, Age 2 to &lt;6 years&#xD;
                       maximum serum creatinine 0.8, Age 6 to &lt;10 years maximum serum creatinine&#xD;
                       1.0, Age 10 to &lt;13 years maximum serum creatinine 1.2, Age 13 to &lt;16 years&#xD;
                       maximum serum creatinine 1.5 for males and 1.4 for females, Age 16 to &lt;18&#xD;
                       years maximum serum creatinine 1.7 for males and 1.4 for females.&#xD;
&#xD;
               -  Urine protein meeting the following parameters:&#xD;
&#xD;
                    -  for participants ≥18 years of age: &lt;2+ on dipstick or routine urinalysis. If&#xD;
                       urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour&#xD;
                       urine must be collected and must demonstrate &lt;2 grams of protein in 24 hours&#xD;
                       to allow participation in the study.&#xD;
&#xD;
                    -  for participants &lt;18 years of age: ≤30 milligrams per deciliter urine&#xD;
                       analysis or &lt;2+ on dipstick. If urine dipstick or routine analysis indicates&#xD;
                       proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate&#xD;
                       &lt;1 g of protein in 24 hours to allow participation in the study.&#xD;
&#xD;
          -  Adequate liver function:&#xD;
&#xD;
               -  Total bilirubin: ≤1.5×ULN. Except participants with document history of Gilbert&#xD;
                  Syndrome who must have a total bilirubin level of &lt;3.0×ULN.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): ≤2.5×ULN OR&#xD;
                  ≤5.0×ULN if the liver has tumor involvement.&#xD;
&#xD;
          -  The participant has an adequate coagulation function as defined by International&#xD;
             Normalized Ratio ≤1.5 or prothrombin time ≤1.5×ULN, and partial thromboplastin time&#xD;
             ≤1.5×ULN if not receiving anticoagulation therapy. For participants receiving&#xD;
             anticoagulants, exceptions to these coagulation parameters are allowed if they are&#xD;
             within the intended or expected range for their therapeutic use. Participants must&#xD;
             have no history of clinically significant active bleeding (defined as within 14 days&#xD;
             of first dose of study drug) or pathological condition that carries a high risk of&#xD;
             bleeding (for example, tumor involving major vessels or known esophageal varices).&#xD;
&#xD;
          -  The participant has adequate hematologic and organ function ≤1 week (7 days) prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to randomization. Male and female participants must&#xD;
             agree to use highly effective contraception for the duration of the study and up to 3&#xD;
             months following the last dose of ramucirumab and 6 months following the last dose of&#xD;
             docetaxel and gemcitabine in order to prevent pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with severe and/or uncontrolled concurrent medical disease or psychiatric&#xD;
             illness/social situation that in the opinion of the investigator could cause&#xD;
             unacceptable safety risks or compromise compliance with the protocol.&#xD;
&#xD;
          -  Participants who have active infections requiring therapy.&#xD;
&#xD;
               -  Participants with an active fungal, bacterial, and/or known severe viral&#xD;
                  infection including, but not limited to, human immunodeficiency virus (HIV) or&#xD;
                  viral (A, B, or C) hepatitis (screening is not required).&#xD;
&#xD;
          -  Participants who have had allogeneic bone marrow or solid organ transplant are&#xD;
             excluded.&#xD;
&#xD;
          -  Surgery: Participants who have had, or are planning to have, the following invasive&#xD;
             procedures are not eligible:&#xD;
&#xD;
               -  Major surgical procedure, laparoscopic procedure, or significant traumatic injury&#xD;
                  within 28 days prior to enrollment.&#xD;
&#xD;
               -  Central line placement or subcutaneous port placement is not considered major&#xD;
                  surgery.&#xD;
&#xD;
               -  Core biopsy, fine needle aspirate, and bone marrow biopsy/aspirate are not&#xD;
                  considered major surgeries.&#xD;
&#xD;
               -  Surgical or other wounds must be adequately healed prior to enrollment.&#xD;
&#xD;
          -  Bleeding and thrombosis:&#xD;
&#xD;
               -  Participants with evidence of active bleeding or a history of significant (≥Grade&#xD;
                  3) bleeding event within 3 months prior to enrollment are not eligible.&#xD;
&#xD;
               -  Participants with a bleeding diathesis or vasculitis are not eligible.&#xD;
&#xD;
               -  Participants with known or prior history in the prior 3 months of esophageal&#xD;
                  varices are not eligible.&#xD;
&#xD;
               -  Participants with a history of deep vein thrombosis requiring medical&#xD;
                  intervention (including pulmonary embolism) within 3 months prior to study&#xD;
                  enrollment are not eligible.&#xD;
&#xD;
               -  Participants with a history of hemoptysis or other signs of pulmonary hemorrhage&#xD;
                  within 3 months prior to study enrollment are not eligible.&#xD;
&#xD;
          -  Cardiac:&#xD;
&#xD;
               -  Participants with a history of central nervous system (CNS) arterial/venous&#xD;
                  thromboembolic events (VTEs) including transient ischemic attack (TIA) or&#xD;
                  cerebrovascular accident (CVA) within 6 months prior to study enrollment are not&#xD;
                  eligible.&#xD;
&#xD;
               -  Participants with myocardial infarction or unstable angina within the prior 6&#xD;
                  months.&#xD;
&#xD;
               -  Participants with New York Heart Association Grade 2 or greater congestive heart&#xD;
                  failure (CHF).&#xD;
&#xD;
               -  Participants with serious and inadequately controlled cardiac arrhythmia.&#xD;
&#xD;
               -  Participants with significant vascular disease (eg, aortic aneurysm, history of&#xD;
                  aortic dissection).&#xD;
&#xD;
               -  Participants with clinically significant peripheral vascular disease.&#xD;
&#xD;
          -  Participants who have a history of fistula, gastrointestinal (GI) ulcer or&#xD;
             perforation, or intra-abdominal abscess within 3 months of study enrollment are not&#xD;
             eligible.&#xD;
&#xD;
          -  Participants with a history of hypertensive crisis or hypertensive encephalopathy&#xD;
             within 6 months of study enrollment are not eligible.&#xD;
&#xD;
          -  Participants who have non-healing wound, unhealed or incompletely healed fracture, or&#xD;
             a compound (open) bone fracture at the time of enrollment are not eligible.&#xD;
&#xD;
          -  Participants previously treated and progressed on combination gemcitabine and&#xD;
             docetaxel regimen. Participants who received combination as maintenance therapy,&#xD;
             without progression, would be eligible.&#xD;
&#xD;
          -  Participants with a known hypersensitivity to ramucirumab, gemcitabine, docetaxel, or&#xD;
             agents formulated with Polysorbate 80.&#xD;
&#xD;
          -  Hepatic impairment:&#xD;
&#xD;
               -  Severe liver cirrhosis Child-Pugh Class B (or worse).&#xD;
&#xD;
               -  Cirrhosis with a history of hepatic encephalopathy.&#xD;
&#xD;
               -  Clinically meaningful ascites resulting from cirrhosis and requiring ongoing&#xD;
                  treatment with diuretics and/or paracentesis.&#xD;
&#xD;
               -  History of hepatorenal syndrome.&#xD;
&#xD;
          -  The participant has a bowel obstruction, history or presence of inflammatory&#xD;
             enteropathy or extensive intestinal resection (eg, hemicolectomy or extensive small&#xD;
             intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or&#xD;
             chronic diarrhea.&#xD;
&#xD;
          -  The participant has symptomatic interstitial pneumonia or pulmonary fibrosis (or&#xD;
             consistent findings of interstitial pneumonia/pulmonary fibrosis on imaging).&#xD;
&#xD;
          -  Participants with central nervous system (CNS) involvement are ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>205-638-2984</phone>
    </contact>
    <investigator>
      <last_name>Gregory Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-546-0990</phone>
    </contact>
    <investigator>
      <last_name>Alok Kothari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-669-2101</phone>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-206-7625</phone>
    </contact>
    <investigator>
      <last_name>Noah Federman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-509-8344</phone>
    </contact>
    <investigator>
      <last_name>Josephine HaDuong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(720) 777-6740</phone>
    </contact>
    <investigator>
      <last_name>Margaret Ellen Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>202-476-4744</phone>
    </contact>
    <investigator>
      <last_name>AeRang Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>239-343-5437</phone>
    </contact>
    <investigator>
      <last_name>Emad Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-2000</phone>
    </contact>
    <investigator>
      <last_name>Steven Attia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-227-4834</phone>
    </contact>
    <investigator>
      <last_name>David Walterhouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-944-1900</phone>
    </contact>
    <investigator>
      <last_name>Melissa Bear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Natalie Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>734-615-7790</phone>
    </contact>
    <investigator>
      <last_name>Rajen J Mody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>612-626-3593</phone>
    </contact>
    <investigator>
      <last_name>Emily Greengard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Mercy Pediatric Clinical Research Unit</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-302-6808</phone>
    </contact>
    <investigator>
      <last_name>Kevin F Ginn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-286-2584</phone>
    </contact>
    <investigator>
      <last_name>Brian A Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-639-8856</phone>
    </contact>
    <investigator>
      <last_name>Emily Slotkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hosp</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-355-1202</phone>
    </contact>
    <investigator>
      <last_name>Mark Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>503-494-4671</phone>
    </contact>
    <investigator>
      <last_name>Katrina Winsnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>267-426-5414</phone>
    </contact>
    <investigator>
      <last_name>Theodore W Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>412-692-8864</phone>
    </contact>
    <investigator>
      <last_name>Andrew Bukowinski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>241-648-4948</phone>
    </contact>
    <investigator>
      <last_name>Patrick Leavey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-2724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>682-885-4874</phone>
    </contact>
    <investigator>
      <last_name>Karen Albritton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>832-824-4632</phone>
    </contact>
    <investigator>
      <last_name>Jodi Muscal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-745-6754</phone>
    </contact>
    <investigator>
      <last_name>Pooja Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-2114</phone>
    </contact>
    <investigator>
      <last_name>Catherine Albert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>414-456-4170</phone>
    </contact>
    <investigator>
      <last_name>Meghen Browning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61290365375</phone>
    </contact>
    <investigator>
      <last_name>Vivek Bhadri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sydney Children's Hospitals Network</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61298452138</phone>
    </contact>
    <investigator>
      <last_name>Jessica Ryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61385598339</phone>
    </contact>
    <investigator>
      <last_name>Jeremy Lewin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61385595000</phone>
    </contact>
    <investigator>
      <last_name>Lisa Orme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3293324812</phone>
    </contact>
    <investigator>
      <last_name>Bram De Wilde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL- Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3227642376</phone>
    </contact>
    <investigator>
      <last_name>Benedicte Brichard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33478785126</phone>
    </contact>
    <investigator>
      <last_name>Jean Yves Blay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33547306088</phone>
    </contact>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33144324068</phone>
    </contact>
    <investigator>
      <last_name>Sophie Piperno-Neumann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4976127043010</phone>
    </contact>
    <investigator>
      <last_name>Simone Hettmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>492017232255</phone>
    </contact>
    <investigator>
      <last_name>Uta Dirksen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4940741020622</phone>
    </contact>
    <investigator>
      <last_name>Uwe Kordes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Lombardie</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390223903062</phone>
    </contact>
    <investigator>
      <last_name>Andrea Ferrari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390282244599</phone>
    </contact>
    <investigator>
      <last_name>Alexia Francesca Bertuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390119933278</phone>
    </contact>
    <investigator>
      <last_name>Massimo Aglietta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390498215493</phone>
    </contact>
    <investigator>
      <last_name>Gianni Bisogno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120360605</phone>
    </contact>
    <investigator>
      <last_name>Chitose Ogawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yuki Koga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31715263459</phone>
    </contact>
    <investigator>
      <last_name>Hans Gelderblom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Centrum</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31650006353</phone>
    </contact>
    <investigator>
      <last_name>Natasha van Eijkelenburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034955923113</phone>
    </contact>
    <investigator>
      <last_name>Maria Jose Flor Oncala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034935537116</phone>
    </contact>
    <investigator>
      <last_name>Antonio Lopez Pousa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034932746100</phone>
    </contact>
    <investigator>
      <last_name>Claudia Maria Valverde Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034922678204</phone>
    </contact>
    <investigator>
      <last_name>Josefina Cruz Jurado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034917277516</phone>
    </contact>
    <investigator>
      <last_name>Andres Redondo Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01614463000</phone>
    </contact>
    <investigator>
      <last_name>Martin McCabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital - London</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442034479346</phone>
    </contact>
    <investigator>
      <last_name>Sandra Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00442086426011</phone>
    </contact>
    <investigator>
      <last_name>Robin Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M139WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01617018430</phone>
    </contact>
    <investigator>
      <last_name>Bernadette Brennan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/4Kdc8Gc0Rx6Z00sohuB8vD</url>
    <description>CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>adolescents and young adults (AYAs)</keyword>
  <keyword>adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

